Skip to main content
PharmAbcine Inc. logo

PharmAbcine Inc. — Investor Relations & Filings

Ticker · 208340 ISIN · KR7208340000 KO Manufacturing
Open in API
Filings indexed 461 across all filing types
Latest filing 2024-07-01 Interim / Quarterly Rep…
Country KR South Korea
Listing KO 208340

About PharmAbcine Inc.

http://pharmabcine.com/

PharmAbcine Inc. is a clinical-stage biotechnology company specializing in the development of fully human therapeutic monoclonal antibodies (mAbs). The company focuses on creating innovative treatments for diseases with high unmet medical needs, primarily in oncology, neovascular eye diseases, and other inflammatory and vascular disorders. Utilizing its proprietary human antibody library and discovery technologies, PharmAbcine advances a pipeline of next-generation IgG-based therapeutics. The company's mission is to contribute to human health by providing novel antibody-based drugs to patients.

Recent filings

Filing Released Lang Actions
[기재정정]분기보고서 (2023.09)
Interim / Quarterly Report Classification · 100% confidence The document is a '분기보고서' (Quarterly Report) for the company '주식회사 파멥신' (PharmAbcine Inc.). It contains detailed financial information, including capital changes, debt status, and management discussion, covering the period from 2023-01-01 to 2023-09-30. It is a comprehensive financial report for a period shorter than a full fiscal year, fitting the definition of an Interim/Quarterly Report (IR). 9M 2023
2024-07-01 Korean
[기재정정]사업보고서 (2023.12)
Regulatory Filings Classification · 95% confidence The document is a 'Correction Report' (정정신고) for a previously filed 'Business Report' (사업보고서), which is the Korean equivalent of an Annual Report (10-K). It details specific corrections to financial data (capital raising) and shareholder information. Since it is a formal amendment to an existing annual report, it falls under the category of regulatory filings related to financial reporting. FY 2023
2024-07-01 Korean
[기재정정]분기보고서 (2024.03)
Interim / Quarterly Report Classification · 95% confidence The document is a 'Correction Report' (정정신고) for a previously filed 'Quarterly Report' (분기보고서) by Pharmabcine. It details specific corrections to financial statements, capital financing, and shareholder information. Since it is a formal amendment to a quarterly financial report containing substantive financial data and tables, it is classified as an Interim/Quarterly Report (IR). Q1 2024
2024-07-01 Korean
증권발행결과(자율공시) (제3자배정 유상증자)
Share Issue/Capital Change Classification · 100% confidence The document is a formal announcement regarding the results of a third-party capital increase (share issuance) by PharmAbcine. It details the number of shares issued, the total amount raised, and the payment date. This falls under the category of share issuance and capital changes.
2024-06-28 Korean
기타시장안내 (기업심사위원회 심의결과 안내)
Delisting Announcement Classification · 100% confidence The document is a short announcement from the Korea Exchange regarding the delisting review results for PharmAbcine. It explicitly states the decision of the Corporate Review Committee to delist the company and outlines the timeline for the subsequent KOSDAQ Market Committee meeting. As this is an official notice regarding the potential removal of the company's stock from the exchange, it falls under the Delisting Announcement category.
2024-06-26 Korean
[기재정정]주요사항보고서(유상증자결정)
Share Issue/Capital Change Classification · 100% confidence The document is a 'Major Matters Report' (주요사항보고서) from a Korean company, PharmAbcine, detailing a 'Decision on Paid-in Capital Increase' (유상증자결정). It explicitly states it is a 'Correction Report' (정정신고) regarding a previously filed capital increase plan. This document falls under the category of announcements regarding new share issues and capital structure changes, which is classified as 'SHA' (Share Issue/Capital Change).
2024-06-24 Korean

Browse filings by year

9 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.